This month’s case involves a referral to another physician; a situation where it is imperative that the referring physician provide all vital information about the patient’s condition to the one who is getting the referral.
The aim of the review was to assess the safety and efficacy of oral and parenteral iron for the treatment of RLS.
Although the research found opioid use to have a favorable risk-benefit ratio, other avenues of treatment should be considered before opioid prescription including addressing iron stores and combination therapy.
In this case, a 57-year-old Caucasian woman presented with hypersomnolence and altered mental status after having ingested 20-30 diphenhydramine 25mg tablets.
Increased risk of death more pronounced among those younger than 50 years regardless of indication
Medi USA announced the availability of the restiffic compressive foot wrap for the treatment of restless legs syndrome (RLS).
The Food and Drug Administration (FDA) has approved labeling updates regarding dosage and warnings for Requip (ropinirole; GlaxoSmithKline) tablets.
Opioids appeared to be efficacious for treating symptoms of restless leg syndrome (RLS) but there is no definitive evidence regarding the issue of safety, a study published in Cochrane Database of Systematic Reviews concluded.
Medi USA announced the launch of restiffic compressive foot wrap, a new drug-free option for patients with restless legs syndrome (RLS).
For patients with severe restless legs syndrome (RLS), gabapentin enacarbil (GEn) was shown to significantly improve RLS symptoms and the consequences of these symptoms.
